SEQUENT — Sequent Scientific Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Sequent Scientific, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Interim Report	ARS	ARS	PRESS
Standards:	IAS	—	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	13,616	14,128	14,209	13,697	15,514
Cost of Revenue
Gross Profit	6,099	6,198	5,148	5,579	7,395
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	12,048	13,550	15,022	13,640	14,639
Operating Profit	1,569	579	-813	57.2	874
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,366	529	-1,377	-546	443
Provision for Income Taxes
Net Income After Taxes	1,045	448	-1,220	-296	323
Minority Interest
Net Income Before Extraordinary Items
Net Income	954	410	-1,212	-359	219
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	954	410	-1,212	-359	219
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.1	1.65	-3.2	-1.13	0.991
Dividends per Share